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Introduction. Many health benefits are claimed by individuals and facilities promoting sauna bathing; however themedical evidence
to support these claims is not well established. This paper aims to systematically review recent research on the effects of repeated
dry sauna interventions on human health. Methods. A systematic search was made of medical databases for studies reporting on
the health effects of regular dry sauna bathing on humans from 2000 onwards. Risk of bias was assessed according to the Cochrane
Collaboration guidelines. Results. Forty clinical studies involving a total of 3855 participants met the inclusion criteria. Only 13
studies were randomized controlled trials and most studies were small (𝑛 < 40). Reported outcome measures were heterogeneous
withmost studies reporting beneficial health effects. Only one small study (𝑛 = 10) reported an adverse health outcome of disrupted
male spermatogenesis, demonstrated to be reversible when ceasing sauna activity. Conclusions. Regular dry sauna bathing has
potential health benefits. More data of higher quality is needed on the frequency and extent of adverse side effects. Further study is
also needed to determine the optimal frequency and duration of distinct types of sauna bathing for targeted health effects and the
specific clinical populations who are most likely to benefit.
1. Introduction
Sauna bathing is a form of whole-body thermotherapy that
has been used in various forms (radiant heat, sweat lodges,
etc.) for thousands of years in many parts of the world
for hygiene, health, social, and spiritual purposes. Modern
day sauna use includes traditional Finnish-style sauna, along
with Turkish-style Hammam, Russian Banya, and other
cultural variations, which can be distinguished by the style
of construction, source of heating, and level of humidity.
Traditional Finnish saunas are the most studied to date
and generally involve short exposures (5−20 minutes) at
temperatures of 80∘C–100∘Cwith dry air (relative humidity of
10% to 20%) interspersed with periods of increased humidity
created by the throwing of water over heated rocks [1]. In the
past decade, infrared sauna cabins have become increasingly
popular.These saunas use infrared emitters at different wave-
lengths without water or additional humidity and generally
run at lower temperatures (45–60∘C) than Finnish saunas
with similar exposure times [2]. Both traditional Finnish
and infrared sauna bathing can involve rituals of cooling-of
f periods and rehydration with oral fluids before, during,
and/or after sauna bathing.
Sauna bathing is inexpensive and widely accessible with
Finnish-style saunas more often used in family, group, and
public settings and infrared saunasmore commonly built and
marketed for individual use. Public sauna facilities can be
located within exercise facilities and the relationship between
saunas and exercise, which may include synergistic hormetic
responses, is an area of active research [3–8]. The use of
private saunas, especially involving infrared saunas, is also
increasing and saunas are used for physical therapy in mas-
sage clinics, health spas, beauty salons, and domestic homes.
This trend is capitalising on the call for additional lifestyle
interventions to enhance health and wellness particularly
in populations that have difficulty exercising (e.g., obesity,
chronic heart failure, chronic renal failure, and chronic
liver disease) [9]. Facilities offering sauna bathing often
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claim health benefits that include detoxification, increased
metabolism, weight loss, increased blood circulation, pain
reduction, antiaging, skin rejuvenation, improved cardiovas-
cular function, improved immune function, improved sleep,
stress management, and relaxation. However, rigorous medi-
cal evidence to support these claims is scant and incomplete,
as emphasized in a recent multidisciplinary review of sauna
studies [10].
There is considerable evidence to suggest that sauna
bathing can induce profound physiological effects [4, 11–17].
Intense short-term heat exposure elevates skin temperature
and core body temperature and activates thermoregula-
tory pathways via the hypothalamus [18] and CNS (central
nervous system) leading to activation of the autonomic
nervous system. The activation of the sympathetic ner-
vous system, hypothalamus-pituitary-adrenal hormonal axis,
and the renin-angiotensin-aldosterone system leads to well-
documented cardiovascular effects with increased heart rate,
skin blood flow, cardiac output, and sweating [1, 11]. The
resultant sweat evaporates from the skin surface and produces
cooling that facilitates temperature homeostasis. In essence,
sauna therapy capitalises on the thermoregulatory trait of
homeothermy, the physiological capability of mammals and
birds to maintain a relatively constant core body temperature
with minimal deviation from a set point [19]. It is currently
unclear whether steam saunas invoke the same degree of
physiological responses as dry saunas [20], as the higher
humidity results in water condensation on the skin and
reduced evaporation of sweat [21].
On a cellular level, acute whole-body thermotherapy
(both wet and dry forms) induces discrete metabolic changes
that include production of heat shock proteins, reduction
of reactive oxygenated species, reduced oxidative stress and
inflammation pathway activities, increased NO (nitric oxide)
bioavailability, increased insulin sensitivity, and alterations
in various endothelial-dependent vasodilatation metabolic
pathways [22]. It has been suggested that heat stress induces
adaptive hormesis mechanisms similar to exercise, and there
are reports of cellular effects induced by whole-body hyper-
thermia in conjunction with oncology-related interventions
(i.e., chemotherapy and radiotherapy) [23]; however the
mechanisms by which the physiological and cellular changes
induced by sauna bathing contribute to enhanced health
and/or therapeutic effects is still being explored [4, 7, 8, 24–
27].
The following systematic review was undertaken to
explore recent research on the clinical effects of repeated dry
sauna bathing (Finnish-style, infrared, or other dry sauna
forms) to document the full range of medical conditions
saunas have been used for, as well as any associated health
benefits and/or adverse effects observed. While a small
number of reviews of sauna bathing and health have been
conducted in the past [1, 2, 28–30], as far as we know, this is
the first systematic review of sauna and health to include both
Finnish and infrared saunas. Furthermore, this review only
considers effects related to regular, multiple sessions of sauna
activity rather than single sauna sessions, to better reflect the
use of sauna bathing as a regular lifestyle intervention.
2. Methods
PRISMA guidelines for conducting systematic reviews were
followed, including the use of validated tools to assess the risk
of bias in randomized controlled trials [70–72].
2.1. Eligibility Criteria. Studies of humans undergoing
repeated dry sauna bathing that reported on health measures
were included in the review. Studies were included for initial
review if they were published in English language from
January 2000 onwards and involved research in humans
undergoing repeated dry sauna sessions with at least one
reported health outcome. Studies involving predominantly
high-humidity (>50%) wet/steam “sauna” or immersion
hydrotherapy were excluded for the potential confounding
mechanisms of differential sweating rates and explicit focus
of this review limited to “dry sauna” interventions. Studies
of partial body heating were excluded since proposed
mechanisms of action may or may not be the same as whole-
body heating. Studies reporting primarily animal-based,
nonhuman findings were excluded given the recognized
differences in end-organ (skin) structure and responses
(sweating mechanisms) between animals and humans.
Studies of “sauna” as a recruitment venue for potential sexual
activity, primarily regarding men who have sex with men
(MSM), were excluded since these studies lacked details
of sauna interventions, confounding whether wet or dry
interventions, andmeasured healthmetrics focused to sexual
activity but not necessarily to sauna activity.
2.2. Search Strategy. PubMed, Web of Science, Scopus, and
Proquest were initially searched with keyword “sauna” and
date restrictions of January 2000–April 2017. Search dates
were chosen to focus on updated findings reflecting advanc-
ing technology in both diagnostics and physiological mon-
itoring to build upon the foundational literature of prior
nonsystematic clinical reviews of sauna activity published in
the early 2000s. After further restrictions of English language
and humans, records were then expanded using Google
Scholar, with searches for other research by key authors,
searches of citations and reference lists of original and review
articles, and other “related articles”. Additional searches with
expanded keywords relating to sauna including “interven-
tional study”, “whole body hyperthermia”, and “whole body
thermotherapy” were also conducted with the same initial
restrictions.
2.3. Data Extraction. Abstracts of initially identified studies
were screened by investigator JH and then the complete
full-text articles of potentially eligible studies were carefully
screened by both investigators JH and MC for research
design, population descriptive data, timing and physical
details of dry sauna intervention, outcome measures, key
results, and adverse effects. Discrepancies regarding inclusion
of studies or data extraction were discussed until consensus
was reached.
2.4. Assessment for Risk of Bias. Included randomized con-
trolled trials (RCTs)were assessed for risk of bias according to
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Jan 2000–April 2017
PubMed
484 citation(s)
Jan 2000–April 2017
843 citation(s)
Web of Science
Jan 2000–April 2017
803 citation(s)
Scopus
Jan 2000–April 2017
1155 citation(s)
Proquest-Health and Medicine
906 nonduplicate
citations screened
Inclusion-English language and human
Exclusion-gay (MSM) focus, steam/wet sauna, hydrotherapy,
partial body heating, animal-based studies, sauna-personal name
738 articles excluded
aer title/abstract screen
168 articles retrieved
Same inclusion/exclusion
criteria applied to full text
40 articles included
99 articles excluded
aer full-text screen
29 articles excluded
during data extraction
Figure 1: PRISMA flow diagram of evidence searches and inclusions/exclusions.
the Cochrane Collaboration’s tool for assessing bias and cal-
culated Jadad et al. scores [72]. Domains of bias assessed were
selection bias (by looking for random sequence generation
and allocation concealment), performance bias (by published
mention of blinding of participants and personnel), detection
bias (by documented attempts to blind outcome assessment),
attrition bias (by evaluating for incomplete outcome data),
reporting bias (by any indication of selective reporting of
outcomes), and other bias (e.g., conclusions not clearly
supported by reported outcomes). Risk of bias was initially
assessed by investigator JH as “low”, “unclear”, or “high” and
then confirmed by investigator MC. Any discrepancies were
discussed until consensus was reached.
3. Results
3.1. Literature Search. Figure 1 summarises the screening and
assessment strategies used with the search results. Of the 906
nonduplicate citations initially identified, 738 were excluded
after a review of the abstracts.
After retrieving 168 full-text articles and applying the
same exclusion criteria as discussed above along with exclud-
ing review articles, case reports, and letters to the editor, 69
independent human studies involving dry sauna interven-
tions were identified for further analysis.
In the data extraction step, one study was excluded since
it was essentially a case series with two patients, mistakenly
identified as an interventional trial conducted by a key
author [73]. Another 28 studies were excluded due to the
intervention being only a single session of sauna and not
repeated sauna therapy, which is the stated focus of this
review.
A total of 40 studies remained for inclusion in this
systematic review. A summary of extracted data is presented
in Tables 1–7, with tables categorised according to participant
population.
3.2. Study Design. Of the forty studies, 13 were randomized
controlled trials (RCTs), 6 were trials with nonrandomized
control groups and 2 were prospective cohort studies. The
remainder of studies were single-group or multigroup inter-
ventional trials (without a control group) or retrospective
studies. The following three levels of evidence were used to
help stratify the quality of the studies.
Levels of Evidence
Level I: multicentre or single-centre, randomized
controlled trial (RCT)
Level II: controlled interventional trial; prospective
cohort study
Level III: retrospective comparative study; case-
control study; pilot study.
3.3. Limitations/Risk of Bias. Many studies were relatively
small, with limited number of participants, and a limited
number of randomized studies were available for review. Of
the 13 randomized controlled trials (RCTs) identified, only 3
of these studies (involving 343/840 participants) [31, 50, 58]
were assessed with having a low overall risk of bias according
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Table 8: Risk of bias assessment in randomized controlled trials.
Random
sequence
generation
Allocation
concealment
Blinding of
participants
and
personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting Other bias
Jadad et al.
score [72]
Fujita et al. 2011 × ? × × ✓ ✓ ? <3
Hu¨ppe et al.
2009 × ? ✓ ✓ ✓ × ? <3
Kanji et al. 2015 ✓ ✓ ✓ ✓ ✓ ✓ ✓ 4
Kihara et al.
2004 × ? × × ✓ ? ? <3
Kunbootsri et al.
2013 × ? × × ✓ ✓ ? <3
Kuwahata et al.
2011 × ? × × ✓ ✓ ? <3
Masuda et al.
2004 × ? × × ✓ ✓ × <3
Masuda et al.
2005 -pain ✓ ? × × ✓ ✓ × <3
Masuda et al.
2005
-depression
× ? × × ✓ ✓ × <3
Miyata et al.
2008 × ? × × ✓ ✓ ? <3
Pach et al. 2010 ✓ ? ✓ ✓ ✓ ✓ ? 5
Shinsato et al.
2010 × ? × × ✓ ✓ ? <3
Tei et al. 2016 ✓ ? × ✓ ✓ ✓ ? 3
✓: low risk of bias; ×: high risk of bias; ?: unclear risk of bias.
to the Cochrane Collaboration criteria [71] and a Jadad et al.
score > 3 [72]. Nine of these 13 RCTs enrolled fewer than 50
participants. Table 8 summarises the assessments of the RCTs
for overall risk of several types of bias.
The follow-up time of many of the studies was relatively
short, in the order of weeks to months, thereby possibly com-
promising detectability and reporting of long-term health
effects over years.
3.4. Setting and Participant Characteristics. The reviewed
studies included a total of 3855 participants living in 12
different countries. Over half of the studies (22 of 40)
originated in Japan. The smallest study involved Australian
athletes (𝑛 = 7) and the two largest studies (both prospective
cohort studies) involved the same cohort of 2315 Finnishmen
[38, 39, 61].Most studies had small sample sizes with over half
(21 of 40 studies) involving 30 or less participants.
The studies involved a range of healthy and disease
populations with 6 studies of healthy individuals, 19 studies
of people diagnosed with cardiovascular disease (CVD) or
increased risk for CVD (i.e., congestive heart failure, type 1
or type 2 diabetes mellitus, and peripheral arterial disease), 7
studies of patients diagnosed with rheumatological, chronic
pain, or mood disorders, 4 studies of patients diagnosed with
airway-related disorders (i.e., chronic obstructive pulmonary
disease, allergic rhinitis), 2 studies of elite athletes, and 2
studies of populations overburdened with environmental
toxicants.
3.5. Interventions. Eleven studies investigated the use of
Finnish saunas and 25 studies utilised infrared sauna inter-
ventions. The remainder 4 studies used other forms of dry
sauna (Thai-style or mixed). Sauna sessions varied from 5
minutes to 20 minutes in single or multiple sessions totaling
30 minutes–4 hours daily, once to several times each week
over study durations that ranged from 3 days to 5 months.
The cohort studies followed frequent infrared sauna bathers
for 5 years and frequent male Finnish sauna bathers for over
20 years.
All of the studies involving Finnish-style saunas used
interventions ranging in temperature from 80 to 90∘C with
relative humidity levels of 10–20% except Hu¨ppe et al. 2009,
a study comparing detoxification protocols, which employed
a lower temperature sauna at 50–65∘C with 30% relative
humidity for 15 minutes in one intervention arm [68].
Of the 25 studies involving infrared sauna, all used
far-infrared types except Ross and Sternquist 2012, which
employed a full-spectrum infrared sauna as part of a
detoxification protocol for policemen [69]. All infrared
sauna studies entailed sauna exposures at 60∘C for 15–30
minutes with the exception of two studies: Amano et al.
2015 studying the effects of sauna on patients diagnosed
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with chronic fatigue syndrome/myalgic encephalomyelitis
(CFS/ME) using saunas set at 40∘C–45∘C for 15 minute
sessions [54] and Oosterveld et al. 2009 examining the effects
of sauna set at 55∘C for 30-minute sessions on patients
diagnosed with Ankylosing Spondylitis and Rheumatoid
Arthritis [53].
All of the sauna interventions were conducted in super-
vised settings (i.e., in-hospital, rehabilitation hospitals, health
centres, university or medical laboratories, and outpatient
programs) except Kanji et al. 2015, which provided sauna
voucher cards to allow participants to attend saunas of choice
attached to local swimming pools [50] and the two large
cohort studies that followed Finnish men attending saunas of
their choice [38, 39].
3.6. Outcome Measures. Some studies focused solely on
measuring subjective quality of life and symptom scoring
surrounding sauna activity such as SF-36 (36-item short
form health survey); FASE (Foundation for Advancements
in Science and Education) 50-item survey of symptoms and
sleep, CMI (Cornell Medical Index) survey of somatic com-
plaints; VAS (visual analogue scales) for hunger, relaxation,
and specific types of pain (i.e., leg pain); various numeric
rating scales for pain, fatigue, sleep quality, and common cold
symptoms; validated tools for depression, anxiety, headache
disability, and anger such as POMS (profile of mood states)
questionnaire, BDI (Beck Depression Inventory), SRQ-D
(self-rating questionnaire for depression), Zung SDS (self-
rating depression scale), STAI (state-trait anxiety inventory
questionnaire), andHDI (HeadacheDisability Index) [43, 50,
51, 54, 55, 69].
Other interventional studies focused on obtaining objec-
tive measures related to sauna activity. For example, the
studies involving CHF patients tracked combinations of
physiological changes using body weight, body temperature,
HR (heart rate) or PR (pulse rate) and SBP and DBP
(systolic and diastolic blood pressures); exercise tolerance
using the 6MWD(6-minute walking distance) and peakVO2
(peak/maximum volume of oxygen) on bicycle ergometer;
cardiomegaly/heart enlargement using CTR (cardiothoracic
ratio) on CXR (chest X-ray); cardiac flow performance
using standard ECHO (echocardiogram) Doppler ultra-
sound parameters; overall functional state using clinician-
based NYHA (New York Heart Association) classification;
endovascular reactivity using FMD (flow-mediated dilation
of brachial artery); heart failure activity using plasma levels
of BNP (B-natriuretic peptide); autonomic nervous system
and immune-mediated activity using ECG (electrocardio-
gram) recordings with heart rate variability parameters and
plasma levels of norepinephrine, TNF-𝛼 (tumour necrosis
factor-alpha), and CD34+ (cluster of differentiation 34, bone
marrow derived) cells; endovascular activity using plasma
levels of VEGF (vascular endothelial growth factor), nitric
oxide metabolites (nitrate and nitrite), and reactive oxygen
metabolites (hydroperoxide) [31–33, 35, 36, 41, 42, 46, 48].
Studies involving patients with increased cardiovascular risk
or studies of healthy patients with aims of detecting changes
in cardiovascular risk with sauna activity used some of the
same physiological parameters mentioned above as well as
serum lipid profiles (total cholesterol, LDL, HDL, and triglyc-
erides), fasting plasma glucose levels, serum levels of uric
acid (potential marker of insulin resistance and metabolic
syndrome), plasma levels of ghrelin, serum levels of leptin,
plasma levels of Hb (hemoglobin) and HCT (haematocrit),
and urinary prostaglandin levels [37, 47, 49, 63, 66, 67].
Other specific objective outcome measures performed
before/after sauna includemyocardial perfusion scintigraphy
with adenosine, treadmill exercise stress test results, flow-
mediated vasodilation of brachial artery, and expression
of CD34-positive bone marrow-derived cells in hospital
patients with ischemic heart disease and total coronary
occlusion; standard spirometry parameters, peak nasal inspi-
ratory flows, and ECG (electrocardiogram) with HRV (heart
rate variability) parameters in participants diagnosed with
allergic rhinitis; plasma volume changes (calculated from
hemoglobin readings), hydration status using urine specific
gravity, exercise performance on ergometer, and ECG with
HRV parameters in elite athletes; axillary body tempera-
tures, venous blood gas panels, lipid peroxidation by UV
(ultraviolet light) and fluorescence analysis, and nitric oxide
levels in elite athletes; transepidermal water loss, stratum
corneum hydration, skin erythema, skin surface pH, surface
sebum contents, and NaCl (sodium chloride) concentrations
in sweat of healthy men and women; basic physiological
observations (temperature, heart rate, blood pressure, and
body weight), calculated plasma volumes, and serum levels
of thyroid function (TSH (thyroid stimulating hormone),
T3, and T4) and other hormones (human growth hor-
mone, adrenocorticotropic hormone, and cortisol) in healthy
women; and pre-and postintervention semen analysis includ-
ing standard sperm parameters, sperm chromatin structure
analysis, sperm apoptosis, quantitative sperm heat-stress
gene expression levels, and plasma levels ofmale sex hormone
levels (LH (luteinizing hormone), FSH (follicle stimulating
hormone), testosterone, and inhibin) in healthy men.
Other interventional studies employed a combination of
subjective and objective measures. Shinsato et al. 2010 and
Tei et al. 2007 compared VAS for leg pain as well as 6MWD
(6-minute walking distance), ABI (ankle/brachial index), leg
blood flows with Doppler laser imaging and angiography,
gene expression levels of CD34+ blood cells and serum levels
of VEGF, and nitrates and nitrites in patients hospitalised
with peripheral artery disease [34, 45]. Kikuchi et al. 2014 and
Umehara et al. 2008 assessed modified Borg dyspnoea scale
or SGRQ (St George’s Respiratory Questionnaire) in addition
to basic physiological observations (temperature, BP, HR,
respiratory rate, and O2 saturation), standard spirometry and
ECHO parameters, 6MWD or ergometer exercise tolerance,
and plasma levels of BNP, HCT, and albumin in hospi-
talised patients with COPD [59, 60]. Oosterveld et al. 2009
utilised subjective VAS and validated tools of EPM-ROM
(Escola Paulista de Medicina-range of motion), DUTCH-
AIMS (Dutch arthritis impact measurement scales), BASMI
(Bath Ankylosing Spondylitis functional index range of
motion), and BASDAI (Bath Ankylosing Spondylitis disease
activity index), as well as serum levels of ESR (erythrocyte
sedimentation rate) [53]. Hu¨ppe et al. 2009 used several
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self-assessed validated scoring tools: Beschwerden-Liste 24-
item questionnaire of somatic symptoms, ADS-L/CES-D 20-
item questionnaire of general depression, and SF-36 quality
of life questionnaire. Objective tests of neuropsychologi-
cal processing speed (GT-MT/ZVT scoring), concentration
(attention test d2), memory power and speed (WL-N and
WL-G scoring, resp.), and serum levels of three different
PCB (polychlorinated biphenyl) congeners, hexachloroben-
zene, DDT (dichlorodiphenyltrichloroethane), and DDE
(p-dichlorodiphenylethylene) were measured before and/or
after sauna interventions [68].
The two largest prospective cohort studies (𝑛 = 2315)
tracked the incidence of dementia, Alzheimer’s disease,
and other cardiovascular disease-related outcomes such as
sudden cardiac death, fatal coronary artery disease, fatal
cardiovascular disease, and all-cause mortality over 20+
years, stratified by sauna bathing one time each week, 2-3
times each week, or 4−7 times each week [38, 39]. The one
retrospective cohort study (𝑛 = 129) tracked episodes of
cardiac death, cardiac events, and rehospitalisations due to
congestive heart failure after completion of an in-hospital 5-
day sauna program followed by twiceweekly outpatient sauna
activity over 5 years [44].
3.7. Health Outcomes
3.7.1. Cardiovascular Disease. The findings of the 9 studies
that researched sauna therapy for congestive heart failure
(CHF) in adults culminated in the largest and most recent
prospective multicentred randomized controlled trial involv-
ing 149 patients with advanced CHF that demonstrated small
but improved 6-minute walking distances (−44.9m ± SD
49.3m, 𝑝 < 0.05), reduced cardiothoracic ratios on chest X-
ray (−1.58% ± SD 2.81%, 𝑝 < 0.05) reflecting reduced heart
sizes, and improved NYHA (New York Heart Association)
classifications of disease (fewer class III and IV patients, 𝑝 <
0.05) after 2 weeks of sauna therapy, all compared to no
significant respective changes in a control group that received
standard medical care [31].
A study of 12 infants with ventricular septal defects
(VSDs) and related severe CHF (congestive heart failure) who
underwent sauna bathing for 5 minutes daily for 4 weeks
demonstrated decreased VSD (ventricular septal defect)
shunt flow ratios (𝑝 < 0.05), which averted the need for
surgical repair in 9 infants [41].
Another randomized controlled trial examined the effects
of repeated sauna therapy on ventricular arrhythmias in 30
subjects with congestive heart failure and more than 200
premature ventricular contractions (PVCs) per 24 hours at
baseline and reported significantly fewer PVCs (mean 848
± 415 versus baseline mean 3097 ± 1033 per 24 hours, 𝑝 <
0.01) after 2 weeks of repeated sauna sessions compared
with no significant changes in a control group that received
conventional medical therapy [36].
Two studies investigated the effects of repeated sauna
sessions on patients with peripheral arterial disease. The
first study was a pilot trial which reported decreased visual
analogue scale (VAS) pain scores (𝑝 < 0.01), improved 6-
minute walking distance (6MWD) (𝑝 < 0.01), improved
ankle/brachial index (ABI) (𝑝 < 0.01), and an increase in vis-
ible collateral vessels in ischemic legs with digital subtraction
angiography (𝑝 < 0.01) observed after 10 weeks of repeated
sauna therapy in twenty patients [45].The second study was a
randomized controlled trial (𝑛 = 21) which reported similar
decreases in VAS (visual analogue scale) leg pain scores (𝑝 <
0.05), increases in 6MWD (𝑝 < 0.01), and improved ABI
(𝑝 < 0.01) in the sauna treatment group compared with
no change in the control group that received conventional
medical therapy. The investigators of this second study also
demonstrated a 2-fold increase in mRNA CD34/GAPDH
expression in peripheral bloodmononuclear cells (𝑝 = 0.015)
and increases in serum nitrate and nitrite levels (𝑝 < 0.05,
𝑝 < 0.05) in the sauna group with no respective changes in
the control group and no significant changes in serum VEGF
levels in either group [34].
Another randomized controlled trial examined the effects
of repeated sauna therapy on 24 ischemic heart disease
subjects with chronic total occlusion of coronary arteries
detected on coronary angiogram who had failed or rejected
attempts at percutaneous coronary intervention or who had
vessels deemed unsuitable for operative interventions. This
study revealed that, after 3 weeks of daily (5 times weekly)
infrared sessions, the scoring indices of defect reversibility
on myocardial perfusion scans (summed stress scores and
summed difference scores) improved (16 ± 7 to 9 ± 6, 𝑝 <
0.01, and 7 ± 4 to 3 ± 2, 𝑝 < 0.01) after sauna therapy but not
in the control group that received standardmedical care [40].
The two largest studies of this review which prospectively
followed 2315 men in Finland over 20.7 years of frequent
sauna bathing for cardiovascular disease-related outcomes
used multivariate analysis and calculated hazard ratios (HR)
adjusting for confounding factors such as blood pressure,
resting heart rate, smoking status, Type 2 diabetes, previous
myocardial infarction, LDL levels, and alcohol consumption.
Their findings included a 66% risk reduction [HR 0.34
(0.16–0.71), 𝑝 = 0.004] of dementia, a 65% risk reduction
[HR 0.35 (0.14–0.90), 𝑝 = 0.03] of Alzheimer’s disease, a 63%
risk reduction [HR 0.37 (0.18–0.75), 𝑝 = 0.005] of sudden
cardiac death, and a 40% risk reduction [HR0.60 (0.46–0.80),
𝑝 < 0.001] of all-cause mortality [38, 39].
3.7.2. Rheumatological and Immune-Mediated Disease. A
Dutch study of 34 patients diagnosed with either rheuma-
toid arthritis (RA) or ankylosing spondylitis (AS) reported
decreased pain and stiffness in the RA (𝑝 < 0.05) andAS (𝑝 <
0.001) groups during 4 weeks of sauna therapy that was not
sustained after the 4weeks, with no changes in disease activity
being detected in either group based upon range-of-motion
scoring and serum levels of ESR (erythrocyte sedimentation
rate) [53].
A Japanese single-group study of 44 patients diagnosed
with fibromyalgia with or without another rheumatologi-
cal disorder (i.e., systemic lupus erythematosus, systemic
sclerosis, rheumatoid arthritis, Sjogren’s syndrome, Behcet’s
disease, or aortitis syndrome) reported subjective improve-
ments in VAS (visual analogue scale) pain scores (𝑝 <
0.001), reduced symptoms based upon FIQ (fibromyalgia
impact questionnaire) (𝑝 < 0.001), improved quality of
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life indicators on SF-36 (short form 36-item) questionnaire
(𝑝 < 0.01–0.05), and objective findings of fewer number of
tender points (𝑝 < 0.01) palpated on physical exam after
12 weeks of combined far-infrared sauna and underwater
exercise therapy [56].
Two studies of patients diagnosed with chronic fatigue
syndrome/myalgic encephalomyelitis reported subjective
improvements after repeated sauna. Soejima et al. 2015 (𝑛 =
10) reported decreased fatigue (𝑝 = 0.002) on numerical
rating scales and improved scores for anxiety (𝑝 = 0.008),
depression (𝑝 = 0.018), fatigue (𝑝 = 0.005), and performance
status (𝑝 = 0.005) on POMS (profile of mood states) ques-
tionnaire after 4weeks of infrared sauna sessions [55]. Amano
et al. 2015 (𝑛 = 15) noted 77.8% of participants receiving
8 weeks of regular far-infrared sauna therapy improved in
symptoms based upon SF-36 (short form 36-item), SRQ-
D (brief self-rating questionnaire for depression), and STAI
(state-trait anxiety inventory questionnaire) compared to
50% of participants in the control group, who chose not to
undergo sauna therapy [54].
3.7.3. Chronic Pain Syndromes. Two randomized controlled
trials investigated the subjective effects of repeated sauna on
chronic pain disorders. One New Zealand study (𝑛 = 37) of
patients diagnosed with chronic tension headaches reported
a 44% reduction in headache intensity within 6 weeks of the
sauna treatment arm,withmean change in headache intensity
between sauna and control group being 1.27 points (95% CI
0.48–2.07; 𝐹 = 10.17; df = 1,117; 𝑝 = 0.002) [50]. The other
Japanese randomized controlled trial of 46 patients with
chronic pain disorders detected an increased likelihood of
return to work 2 years after sauna intervention (𝑝 < 0.05) and
decreases in anger scoring (on CMI, Cornell Medical Index)
in the 4-week sauna-treated group compared to control
group (4.5 ± 1.1 to 2.2 ± 1.6, 𝑝 < 0.001) who received the
same courses of behavioural/rehabilitation/exercise therapy
without additional sauna therapy [51].
3.7.4. Depression. One randomized controlled trial that
investigated the effects of 4 weeks of sauna sessions on 28
patients diagnosed with mild depression reported improved
somatic complaints (𝑝 < 0.001), improved hunger scores
(𝑝 < 0.0001), and improved relaxation scores (𝑝 <
0.0001) based upon subjective somatic complaint, depres-
sion, hunger, and relaxation scoring in the sauna group
as compared to the control group that received bedrest
instead of sauna therapy. In this same study, plasma ghrelin
concentrations and daily caloric intakes also changed in the
sauna group compared to control group (∗𝑡 = −2.32, 𝑝 <
0.05, and ∗𝑡 = −2.65, 𝑝 < 0.05, resp.) with ∗Student two-
tailed group 𝑡-test [52].
3.7.5. Lungs and Airways. Two studies focused on the effects
of infrared sauna on patients diagnosed with COPD (chronic
obstructive pulmonary disease). One controlled trial (𝑛 =
20) reported improved FEF50 (forced expiratory flow after
50% of expired forced vital capacity) in patients receiving 4
weeks of repeated sauna [+0.08 L/s (0.01–0.212 L/s)] versus a
control group [−0.01 L/s (−0.075–0.04 L/s)], 𝑝 = 0.019, that
received usual medical care. No other changes in spirometry
parameters or 6-minute walk test distances were detected
between the two groups [59]. The second study involved a
single group of male, ex-smoker COPD patients (𝑛 = 13)
with the following findings after 4 weeks of sauna sessions:
improved symptom scores (59.7 pts± 16.9 to 55.3 pts± 17.2 pts,
𝑝 = 0.002); decreased pulmonary artery pressures during
exercise (𝑝 = 0.028); increased exercise times after sauna
exposures (360 s ± 107 s to 392 s ± 97 s, 𝑝 = 0.032); and
improved oxygen saturation during exercise (𝑝 = 0.022) [60].
The Thai randomized controlled trial (𝑛 = 26) that
investigated the effects of a 6-week rehabilitation sauna
program on patients diagnosed with symptomatic allergic
rhinitis reported improved peak nasal inspiratory flow rates
(119.2 L/s ± 46.4 to 161.9 L/s ± 46.7, 𝑝 = 0.002) and improved
FEV1 (forced expiratory volume at 1 sec) (77.5% ± 9.8% to
95.6% ± 5.7%, 𝑝 = 0.002) in the sauna intervention group
compared to a control group that received usualmedical care.
The researchers also examined HRV (heart rate variability)
parameters but detected no significant difference between the
sauna and control groups [57].
Another randomized controlled trial studied common
cold sufferers in Germany (𝑛 = 157) sitting for 3 minutes
fully winter-dressed in a Finnish sauna daily over 3 days
breathing in piped “hot dry” sauna air versus control “cool
dry” room temperature air while wearing a face mask.
Only on day 2 assessment, a decrease in symptom severity
scoring was detected in treatment versus control groups [−1.0
(−2.0–−0.1), 𝑝 = 0.04, 95% CI] but this finding was not
sustained through days 3, 5, and 7 of study. Fewer doses of
cold and flu medications were taken by the treatment group
on day 1 of assessment [3% (1–9%) versus 15% (8–28%), 𝑝 =
0.01, 95% CI], compared to the control group [58].
3.7.6. Athletes. Two small noncontrolled interventional trials
studied the physiological effects of repeat sauna in athletes.
One study (𝑛 = 7) reported that 30 minutes of daily
postexercise sauna bathing for ten days was associated with
peaked expansion of plasma volume after 4 days (+17.8%,
90% CI: 7.4–29.3%), followed by a trend back to presauna
levels by days 7–10 [61]. The other study (𝑛 = 16) noted a
mean postsauna increase in axillary body temp 2.6∘C (𝑝 <
0.001) after first sauna versus a mean increase of only 1.9∘C
(𝑝 < 0.002) after completing a 5 months’ course of sauna
bathing. The researchers also noted postsauna increases in
mean venous pH by 0.8% (𝑝 < 0.001), decreased mean base
excess by 20.3% (𝑝 < 0.001), increased mean venous O2
by 53.3% (𝑝 < 0.001), increased mean Hb concentration
in blood by 5.2% (𝑝 < 0.001), and right shift of oxygen-
hemoglobin dissociation curve (decreased affinity, favours
release of O2 to tissues) after the first sauna with similar
changes in specified parameters noted after a final sauna 5
months later (𝑝 < 0.043–𝑝 < 0.005) [62].
3.7.7. Healthy Populations. Two small uncontrolled, single-
gender studies reported reduced total cholesterol levels (4.50
± 0.66mmol/L to 4.18 ± 0.41mmol/L, 𝑝 = 0.02) and reduced
LDL (low density lipoprotein) levels (2.71 ± 0.47mmol/L to
Evidence-Based Complementary and Alternative Medicine 23
2.43 ± 0.35, 𝑝 = 0.01) in healthy men (𝑛 = 16) after 4 weeks
of regular sauna activity involving 45min sauna sessions [66]
and reduced total cholesterol levels (4.47 ± 0.85mmol/L to
4.25 ± 0.93mmol/L, 𝑝 < 0.05) and reduced LDL levels
(2.83 ± 0.80mmol/L to 2.69 ± 0.83mmol/L, 𝑝 < 0.05) in
healthy women (𝑛 = 9) after 2 weeks of regular sauna
activity involving 30-minute sauna sessions [67]. The same
research group of both studies reported earlier findings of
significant increases in heart rate, systolic blood pressure,
growth hormone, adrenocorticotropic hormone, and cortisol
levels along with significant decreases in diastolic blood
pressure and plasma volumes after single and repeated sauna
sessions in 20 women after 2 weeks of either 30-min sauna
sessions or 45-min sauna sessions [63, 65]. Reductions in total
and LDL cholesterol levels along with increased HDL (high
density lipoprotein) cholesterol levels were reported in the
45-min sauna group.
Another study of healthy men and women examined the
skin physiology of regular sauna attenders (𝑛 = 21) compared
to newcomer sauna attenders (𝑛 = 20) before and after
sauna bathing. The investigators reported a decrease in NaCl
(sodium chloride) sweat concentrations in the regular sauna
group (∼200mmol/L ± ∼10mmol/L to ∼170mmol/L ± ∼
10mmol/L, 𝑝 = 0.0167) without any respective changes in
the newcomer sauna group. Baseline values (presauna) of
forehead sebum level were 25% lower in the regular sauna
group (𝑝 < 0.05) compared with newcomer group but sebum
levels decreased similarly in both groups after sauna. Skin
surface pH was generally measured to be lower in the regular
sauna group but similar scales of pH elevation were recorded
for both groups during and after sauna activity [64].
3.7.8. Detoxification. Populations burdened with toxicants
were the subject of two studies. Both entailed multimodal
therapies with sauna as a prominent but not sole intervention
and both demonstrated improved self-assessed quality of life
measures [68, 69]. Ross and Sternquist 2012 (𝑛 = 69) docu-
mented improved posttreatment SF-36 (short form 36-item
health survey) scores in symptomatic policemen exposed
to employment-related drugs and toxicants compared to
pretreatment scores (with 2-tailed Student 𝑡-test paired scores
and Wilcoxon matched pairs test and sign test, 𝑝 < 0.001),
across all subscales after 4−6 weeks of infrared sauna sessions
with up to 4 hours of sauna bathing daily. The FASE
(Foundation for Advancements in Science and Education)
50-item and neurotoxicity symptom questionnaires further
revealed fewer “poor physical health” days (9.3 versus 1.8
days, 𝑝 < 0.001); fewer “sick days” (2.0 versus 0.3 days,
𝑝 < 0.001); more sleep hours (5.8 versus 7.6 h, 𝑝 < 0.001);
and lessened neurotoxicity scoring (65.5 ± 24.8 versus 14/6 ±
11/5 points, 𝑝 < 0.001) [69].
The other sauna detoxification study was a randomized
controlled trial (𝑛 = 36) of symptomatic individuals with
elevated levels of lipophilic toxicants, comparing two separate
sauna interventions with a control group: (I) steam sauna
with oral and intravenous supplements, (II) dry sauna with
substitute placebo oral and intravenous interventions, and
(III) no sauna, no oral, and no intravenous interventions.
Usingmultivariate analysis of variance (MANOVA)methods,
several somatic well-being scores improved in both treatment
groups (I) and (II), as compared to group (III) with Duncan
post hoc test suggesting significant differences between group
(I) and group (III) (𝑝 < 0.01) and between groups (I) and
(II) (𝑝 < 0.05). No differences however were seen between
groups (II) and (III) (𝑝 = 0.21) and no significant changes
in neuropsychological testing scores (𝑝 > 0.10) or serum
concentrations of selected organochlorides (𝑝 > 0.10) were
reported between any of the groups [68].
3.7.9. Spermatogenesis. One longitudinal time-course study
examined the effects of Finnish sauna activity on male
sperm and fertility measures in 10 healthy men. After 3
months of repeated sauna (15-min saunas twice weekly), the
investigators reported reduced sperm counts (93 ± 27.0 ×
106 versus 223 ± 52.8 × 106, 𝑝 < 0.001); reduced sperm
concentrations (31 ± 13.1 × 106/ml versus 89 ± 29.3 × 106/ml,
𝑝 < 0.001); fewer motile sperm (36.1 ± 3.6% versus 58.0 ±
7.6%, 𝑝 < 0.01); abnormal sperm parameters [decrease in
normal histone-protamine replacement (𝑝 < 0.05); abnormal
chromatin condensation (𝑝 < 0.05); altered mitochondrial
function (𝑝 < 0.01)]; upregulation of various heat-stress
genes [HIF-1𝛼 (𝑝 < 0.001), KDR (𝑝 < 0.001), FLT1 (𝑝 <
0.001), and VEGF (𝑝 < 0.001)]; and upregulation of HSPs
(heat shock proteins) and HSFs (heat shock factors) [HSP90
(𝑝 < 0.001), HSP70 (𝑝 < 0.001), HSF1 (𝑝 < 0.001), HSF2
(𝑝 < 0.001), and HSFY (𝑝 < 0.001)]. However, all specified
changes reverted back to normal 6months after ceasing sauna
activity and no significant changes in plasma sex hormones
from baseline were detected directly after sauna or after 3 or
6 months [27].
3.7.10. Adverse Side Effects. Of the 40 included studies, only
eight reported any adverse symptoms from sauna bathing.
Six studies recorded adverse effects graded as mild, meaning
symptoms of complaint were noted which did not alter the
study protocol or incur dropouts to the study. Mild heat
discomfort was the major complaint [53, 61, 69]. Other mild
complaints noted in one infrared sauna study of heart failure
patients (𝑛 = 149) included symptomatic low blood pressure,
hypovolemia, polyurination, weight loss, and, questionably,
acute bleeding after a tooth extraction [31]. Another study of
patients with peripheral arterial disease (𝑛 = 21) reported
transient leg pain in one participant during a first infrared
sauna session with the pain improving after completing a
few sauna sessions and disappearing altogether by the end of
the 6-week study [34]. Pach et al. 2010 reported coughing in
3 of 157 Finnish-style sauna participants, stimulated by the
placement of a face mask in both intervention and control
groups, with different temperatures of air piped through the
masks of the respective groups [58].
Two studies recorded moderate adverse effects, defined
as symptom complaints that led to dropout of study par-
ticipants or led to changes in study protocols. One study,
involving fifteen women diagnosed with chronic fatigue
syndrome/myalgic encephalomyelitis, reported enough heat
intolerance in “most” of the participants such that the
investigators reduced the temperature of the infrared sauna
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intervention from60∘C to 45∘C to finish conducting the study
[54]. Another infrared sauna study (randomized controlled
trial) of chronic pain patients (𝑛 = 46) reported 2 patients
dropping out of the treatment armdue to acute bronchitis and
claustrophobia experienced in the sauna room [51]. None of
the included studies reported severe adverse effects involving
the need for emergency medical services.
4. Discussion
4.1. Principal Findings. The findings of this review suggest
frequent dry sauna bathing improves a variety of subjective
and objective health parameters and that frequent Finnish
sauna bathing is associated with improved outcomes such as
reduced overall mortality and reduced incidence of cardio-
vascular events and dementia, at least in men [38, 39]. The
most established clinical benefits of sauna bathing are asso-
ciated with cardiovascular disease, yet there is also evidence
to suggest that saunas, either Finnish-style or infrared, may
benefit people with rheumatic diseases such as fibromyalgia,
rheumatoid arthritis, and ankylosing spondylitis, as well as
patients with chronic fatigue and pain syndromes, chronic
obstructive pulmonary disease, and allergic rhinitis. Sauna
bathing may also improve exercise performance in athletes,
skin moisture barrier properties, and quality of life and
is not associated with serious adverse events. There is not
yet enough evidence to distinguish any particular health
differences between repeat Finnish-style and repeat infrared
sauna bathing.
Cardiovascular disease has clearly been a focus for sauna
researchers since 2000 despite Finnish-style sauna being con-
sidered by some in the past as a contraindication for patients
with CHF and other cardiovascular diseases, most likely
because of perceived intolerance to the high temperatures
[1]. Nearly half (19 of 40) of the studies included in this
review involved populations who had active cardiovascular
disease or increased risk for cardiovascular disease, and all
these studies demonstrated beneficial health effects. Seven of
these 19 studies were randomized controlled trials (RCTs),
with only one of them meeting the Cochrane criteria for
an acceptably low risk of bias. This particular multicentre
RCT (𝑛 = 149) reported improvements in all outcome
measures except B-type natriuretic peptide (BNP) levels
(namely, longer 6-minute walking distance, reduced cardio-
thoracic ratio on chest X-ray, and improved NYHA (New
YorkHealthAssociation) classification) in the infrared sauna-
treated congestive heart failure group compared to control
over only 2 weeks of intervention [31].
While sauna bathing appears to show promise as a
lifestyle intervention for cardiovascular disease, a majority
of the cardiovascular disease-related sauna studies (16 of 19)
were conducted by the same core Japanese research group
and affiliates who employed “Waon therapy” [74], which
involved far-infrared sauna bathing. These Waon therapy
studies used similar outcome measures and mostly involved
hospitalised patients, which might reflect some differences in
health care systems and thresholds for hospitalisation. The
use of primarily hospitalised patients in these studies also
brings up issues of how applicable the findings may or may
not be to outpatient populations.
Despite differences in sauna types, temperature, fre-
quency, and duration of interventions, the far-infrared sauna
studies involving cardiovascular disease and congestive heart
failure patients suggest favourable outcomes that reinforce
earlier findings of interventional Finnish sauna studies and
cardiovascular disease [75–79]. This suggests that heat stress,
whether induced by infrared or Finnish-style sauna, causes
significant sweating that is likely to lead to hormetic adap-
tation and beneficial cardiovascular and metabolic effects.
This is further supported by the two large observational
studies that found striking risk reductions for sudden cardiac
death (63%) and all-cause mortality (40%) as well as for
dementia (66%) and Alzheimer’s disease (65%), in men
who used a sauna 4−7 times per week compared to only
once per week [38, 39]. While these large cohort studies
are based on calculated hazard ratios with adjustments for
common cardiac risk factors, it has been pointed out that
the association between sauna activity and health outcomes
may be noncausal and that sauna use is merely an indicator
of “healthy lifestyle” and other socioeconomic confounding
factors [80]. Nevertheless, these findings point to the need
for further study and serious consideration given to sauna
bathing to address the ever-increasing individual, societal,
and financial burdens of cardiovascular disease as well as
dementia-related conditions in aging populations.
4.2. Mechanisms of Action: Sauna Bathing. Several mecha-
nisms of action have been proposed for the health effects
of frequent sauna bathing. Exposure to heat increases
cardiac output and reduces peripheral vascular resistance
and induces other physiological changes in cardiovascular
parameters such as decreased systolic and/or diastolic blood
pressure [31, 35, 37, 46–49, 60, 65], increased HRV (heart rate
variability) [33, 36, 57], improved cardiac function markers
[31, 33, 35, 36, 40, 42, 46, 48], and improved flow-mediated
arterio- and vasodilatation of small and/or large blood vessels
[34, 40, 42, 45, 47–49]. Regarding hormonal and metabolic
models, reduced levels of epinephrine and/or norepinephrine
[42, 46], increased levels of nitric oxide metabolites in blood
[32, 34] and urine [41], decreased total and LDL (low density
lipoprotein) cholesterol levels [63, 66, 67], increased serum
levels of growth hormone, adrenocorticotropic hormone
(ACTH), and cortisol [65], decreased fasting blood glucose
levels [49], increased plasma ghrelin levels [52], and reduced
urinary levels of prostaglandins (8-epi-prostaglandin F2𝛼)
[37] have been detected after regular sauna sessions. Together,
these findings support complex multipathway end-organ
effects on the central and autonomic nervous system, the
peripheral vascular endothelium, and the hypothalamus-
pituitary-adrenal axis, as well as on the kidneys and the liver
that are continuing to be documented [1, 11, 28, 81].
The complexity of how sauna bathing may influence
cardiovascular risk factors is suggested by the report of
beneficial effects on total cholesterol and LDL (low density
lipoprotein) cholesterol and conflicting results on HDL (high
density lipoprotein) levels in healthy young men and women
[63, 66, 67]. These findings, which need to be confirmed
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in larger studies with nonsauna control groups, may point
to differences between Finnish and infrared saunas as they
contrast with previous similarly sized, yet better controlled
studies of infrared sauna bathing in populations at increased
risk of cardiovascular disease [37, 47, 49]. These findings
may also be compared to the metabolic effects of exercise
in healthy populations which include improvements in both
LDL and HDL lipid levels [82].
While there are likely to be many mechanisms of action
influencing the physiological effects of sauna bathing, it has
been suggested that sauna bathing may induce a general
stress-adaptation response that leads to “hormetic adap-
tation” and the establishment of “sauna fitness,” possibly
analogous to the hormetic adaptation responses of exercise.
This is supported by newer, single-cell analysis methods that
suggest sauna bathing increases generation of free radicals
and reactive oxygenated species along with enhanced antiox-
idant activities via proposed nitric oxide- (NO-) dependent
processes in blood [62] and upregulation of specific HSPs
(heat shock proteins) andHSFs (heat shock factors) in semen
[27]. The two studies in athletes further support sauna’s
involvement in hormetic stress responses with the findings
of plasma volume expansion after 4 days of daily postexercise
sauna bathing, followed by a trend back to presauna levels
by days 7–10 in one study [61], along with mean postsauna
increases in axillary body temperature of 2.6∘C after a first
sauna versus mean postsauna increases of only 1.9∘C after
the last session of a 5-month course in the other study [62].
Additionally, increases in plasma lipid peroxidase levels and
increases in free radical processes of RBCs and decreases
in plasma 𝛼-tocopherol (antioxidant) levels and decreases
in RBC catalase activity after an initial sauna were not
maintained after 5 months of regular sauna [62], suggesting
that sauna bathing may upregulate antioxidant defences.
Improved adaptation to stress with regular sauna bathing
may be further enhanced by excretion of toxicants through
heavy sweating. Many industrial toxicants including heavy
metals, pesticides, and various petrochemicals may be
excreted in sweat leading to an enhancement of metabolic
pathways and processes that these toxic agents inhibit [83].
Sweat-induced excretion of toxic metals such as arsenic,
cadmium, lead, andmercury has been reported with the rates
of excretionmatching or exceeding urinary routes [84].There
is also recent evidence that toxic chemicals and xenobiotics
such as polybrominated diphenyl ether (PBDE) flame retar-
dants, organochlorine pesticides, bisphenol-A (BPA), and
phthalates may be excreted via induced sweating at rates
that exceed urinary excretion [85–88]. The importance of
sweat in excretion pathways has been further documented
by sweat-patch technology used to monitor illicit drug use
and is based on dozens of studies of the pharmacodynamics
and pharmacokinetics of amphetamine, cocaine, cannabis,
opiates, and associated metabolites [89, 90]. While sweat-
induced detoxification certainly occurs, studies using sauna
for detoxification purposes report more favourable findings
with subjective rather than objective measures [68, 69].
Further research on sauna-based detoxification is warranted
as the excretory functions of skin via sweating or other active,
passive inter- and/or transcellular, and transdermal pathways
are complex and the role of frequent sweating to promote
excretion and improve health is still poorly defined [91].
In addition to having profound physiological effects,
sauna bathing is reported to have beneficial psychological
effects that are reflected in the many reports of improved
well-being, pain tolerance, and other self-assessed symptom-
related scoring [34, 36, 43, 45, 46, 50–56, 58, 60, 68, 69].
The psychological impact of sauna bathing may be due to
a combination of factors that include release of endorphins
and other opioid-like peptides such as dynorphins [81, 92],
forced mindfulness, psychological stress reduction, relax-
ation, improved sleep, time out from busy life schedules,
placebo effects, and other aspects of individual psychological
and social interactions that likely occur around frequent
sauna activity. While it is difficult to distinguish between the
different factors that produce positive psychological effects,
such effects may enhance other physiological and metabolic
benefits as they are likely to promote adherence to regular
sauna activity.
4.3. Safety and Adverse Effects with Sauna. In the medical
literature at large, there are reports of severe adverse effects
from saunas that include dry sauna-induced burns [93] and
myocardial ischemia (especially in patients with unstable
coronary artery disease) [94], alongwith less frequent reports
of syncope/falls [1], hypersensitivity pneumonitis (“sauna
lung”) [95], nonexertional heatstroke [96], rhabdomyolysis
[93], ocular irritations [97], “sauna stroke syndrome” [98],
and death [99]. The risk of death from saunas was examined
in retrospective population studies of frequent sauna users
in Sweden and Finland, with the annual death rate from
saunas being reported as 0.06 and 2 per 100,000 inhabitants,
respectively, with half or more of all these deaths involving
the use of alcohol and a common risk factor of sauna bathing
alone [99, 100].
In this review, adverse signs and symptoms of both
Finnish-style and infrared sauna bathing were reported as
mild to moderate heat discomfort and intolerance in 4 of the
studies [53, 54, 61, 69], low blood pressure/light-headedness
in one study [31], transient leg pain in another study [34],
airway irritation in two studies [51, 58], and claustrophobia in
one study [51], with no severe adverse symptoms reported in
any studies. Detailed comparative analysis of adverse effects
between studies was limited by small sample sizes, hetero-
geneity of sauna types and study design (many without con-
trol groups), and inconsistent reporting of adverse side effects
within outcome measures. The highest intensity of adverse
effects (moderate levels of heat intolerance) occurred in
populations afflicted with chronic fatigue syndrome, chronic
pain, rheumatoid arthritis, and ankylosing spondylitis. As
these conditions are all associated with inflammation and
abnormal immune responses, it may be that the heat and/or
increased sweating of sauna activity is modulating some of
these responses [51, 53, 54]. The direct adverse effects of heat
may also be responsible for the impairment of sperm counts,
concentration, and motility and upregulation of heat-stress-
related genes reported in the sperm of 10 healthy men after
a 3-month course of Finnish-style sauna [27]. While these
findings are based upon one identified study of only 10 men,
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the findings are consistent with some earlier research on
the effects of genital heat stress on semen quality [101–104].
All the deleterious sperm effects of the sauna intervention
mentioned in this study were observed to revert back to
“normal” presauna levels after 6 months of avoiding sauna
activity [27]. While this supports current recommendations
for men seeking to optimize fertility to avoid sauna-type
activities [105], further research is required to determine
if similar effects on sperm occur with lower temperature
infrared sauna bathing or if sauna bathing has any effect on
male fertility.
4.4. Strengths/Limitations. To the best of our knowledge, this
is the first systematic review to include both Finnish-style
and infrared sauna studies. However, we did not include
studies of steam sauna interventions and therefore may have
overlooked some evidence of the effects of heat on health.
Another limitation of this study is the inclusion of only
English language, especially since sauna activity is frequent in
non-English speaking countries. Furthermore, the quality of
the reviewed studies was variable with many studies having
small sample sizes, poorly described methodology, variable
use of controls, differing types of sauna and sauna protocols,
variable duration and frequency of sauna interventions, and
inconsistent mention of cooling therapies or rehydration
protocols along with heterogeneous outcome measures. The
great heterogeneity of studies makes meaningful compar-
isons across studies difficult and provides insufficient evi-
dence to recommend specific temperature, frequency, or
duration of sauna bathing for any specific health outcome.
In themonths since this systematic reviewwas conducted,
a number of new research findings have been published,
analyzing various subsets of the same Finnish prospective
cohort of over 2000menwho regularly sauna-bathed, initially
aged 42–60 years, followed over 20 years as part of the KIHD
(Kuopio Ischemic Heart Disease) study, as detailed in two of
the studies included inTable 1: cardiovascular disease- (CVD-
) related sauna studies.These newer findings cite reduced risk
of acute and chronic respiratory conditions [106], reduced
risk of pneumonia [107], reduced serum levels of C-reactive
protein (marker of systemic inflammation) [108] with more
frequent sauna bathing, and reduced risk of hypertension
[109] and additional improved all-cause mortality when
jointly associated with cardiorespiratory fitness [110]. These
findings add further support to the conclusions of this review.
4.5. Future Research Perspectives. With the rise of single-
cell analysis and “omics” platforms of analysis such as
metabolomics and transcriptomics, especially applied to
sweat, blood, urine, saliva, and other human biofluids, the
ability to unravel the metabolic pathways at work during
sauna or whole-body thermotherapy will certainly improve.
Further study of these metabolic pathways might also help
to elucidate the stress-related pathways of immune and
inflammatory activity that may be involved in conditions
such as chronic fatigue syndrome, chronic pain, rheumatoid
arthritis, and ankylosing spondylitis.
Studies examining heart rate variability (HRV) as an
outcome assessment are increasing and further results may
better inform the physiological models of what is thought
to be happening with repeated sauna of either Finnish or
infrared types. The concepts of hormetic stress and inter-
relating “sauna fitness” or habituation to the physiological
effects of repeated sauna activity might have implications for
preventive or therapeutic targets in the future. Conducting
more studies of repeated sauna in healthy but nonathletic
participants may further help to elucidate the similarities and
differences in metabolic pathways between repeated sauna
activity and regular exercise. Further studies are also needed
to distinguish between the health effects of Finnish saunas,
which often involve brief periods of increased humidity
and dramatic cooling interventions, compared to the lower
temperature infrared saunas that typically do not have such
variations.
5. Conclusions
Regular infrared and/or Finnish sauna bathing has the
potential to provide many beneficial health effects, especially
for those with cardiovascular-related and rheumatological
disease, as well as athletes seeking improved exercise per-
formance. The mechanisms for these effects may include
increased bioavailability of NO (nitric oxide) to vascular
endothelium, heat shock protein-mediated metabolic activa-
tion, immune and hormonal pathway alterations, enhanced
excretions of toxicants through increased sweating, and other
hormetic stress responses.
Currently there is insufficient evidence to recommend
specific types of sauna bathing for specific clinical conditions.
While regular sauna bathing appears to be well-tolerated in
the clinical setting with only minor and infrequent adverse
effects reported, further data on the frequency and extent of
adverse effects is required. Further studies are also required
to explore the mechanisms by which sauna bathing exerts
physiological, psychological, and metabolic effects, as well
as to better define the benefits and risks of distinct types
of saunas and the optimal frequency and duration of sauna
bathing for beneficial health effects.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Acknowledgments
This manuscript was developed as part of study conducted
by Dr. Joy Hussain during her Ph.D. candidature at RMIT
University. Joy Hussain is supported by a Ph.D. scholarship
from the Jacka Foundation.
References
[1] M. L. Hannuksela and S. Ellahham, “Benefits and risks of sauna
bathing,” American Journal of Medicine, vol. 110, no. 2, pp. 118–
126, 2001.
[2] R. Beever, “Far-infrared saunas for treatment of cardiovascular
risk factors: summary of published evidence,” Canadian Family
Physician, vol. 55, no. 7, pp. 691–696, 2009.
Evidence-Based Complementary and Alternative Medicine 27
[3] T. Brockow, E. Conradi, G. Ebenbichler, A. Michalsen, and
K. L. Resch, “The role of mild systemic heat and physical
activity on endothelial function in patients with increased
cardiovascular risk: results from a systematic review,” Research
in Complementary Medicine, vol. 18, no. 1, pp. 24–30, 2011.
[4] M. Gayda, L. Bosquet, F. Paillard et al., “Effects of sauna
alone versus postexercise sauna baths on short-term heart rate
variability in patients with untreated hypertension,” Journal of
Cardiopulmonary Rehabilitation and Prevention, vol. 32, no. 3,
pp. 147–154, 2012.
[5] A. E. Littmann and R. K. Shields, “Whole body heat stress
increases motor cortical excitability and skill acquisition in
humans,” Clinical Neurophysiology, vol. 127, no. 2, pp. 1521–1529,
2016.
[6] G. M. Minett, M. Skein, F. Bieuzen et al., Heat Acclimation for
Protection from Exertional Heat Stress, The Cochrane Library,
2016.
[7] E. J. Calabrese and L. A. Baldwin, “Defining hormesis,” Human
and Experimental Toxicology, vol. 21, no. 2, pp. 91–97, 2002.
[8] M. P. Mattson, “Hormesis defined,” Ageing Research Reviews,
vol. 7, no. 1, pp. 1–7, 2008.
[9] R. Arena, K. Berra, L. Kaminsky et al., “Healthy lifestyle
interventions to combat noncommunicable disease—a novel
nonhierarchical connectivity model for key stakeholders: a pol-
icy statement from the American Heart Association, European
Society of Cardiology, EuropeanAssociation forCardiovascular
Prevention and Rehabilitation, and American College of Pre-
ventive Medicine,” European Heart Journal, vol. 36, no. 31, pp.
2097–2109, 2015.
[10] J. Tsonis, “Sauna studies as an academic field: a new agenda for
international research,” Literature and Aesthetics, vol. 26, no. 1,
2017.
[11] K. Kukkonen-Harjula, P. Oja, K. Laustiola et al., “Haemody-
namic and hormonal responses to heat exposure in a Finnish
sauna bath,” European Journal of Applied Physiology, vol. 58, no.
5, pp. 543–550, 1989.
[12] W. J. Crinnion, “Sauna as a valuable clinical tool for cardiovas-
cular, autoimmune, toxicant-induced and other chronic health
problems,” Alternative Medicine Review, vol. 16, no. 3, pp. 215–
225, 2011.
[13] J. Leppaluoto, P. Huttunen, J. Hirvonen, A. Va¨a¨na¨nen, M.
Tuominen, and J. Vuori, “Endocrine effects of repeated sauna
bathing,” Acta Physiologica Scandinavica, vol. 128, no. 3, pp.
467–470, 1986.
[14] D. Jezova, Z. Radikova, and M. Vigas, “Growth hormone
response to different consecutive stress stimuli in healthy men:
is there any difference?” Stress, vol. 10, no. 2, pp. 205–211, 2007.
[15] T. Radtke, D. Poerschke, M. Wilhelm et al., “Acute effects of
Finnish sauna and cold-water immersion on haemodynamic
variables and autonomic nervous system activity in patients
with heart failure,” European Journal of Preventive Cardiology,
vol. 23, no. 6, pp. 593–601, 2016.
[16] C. Tomiyama, M. Watanabe, T. Honma et al., “The effect
of repetitive mild hyperthermia on body temperature, the
autonomic nervous system, and innate and adaptive immunity,”
Biomedical Research (Japan), vol. 36, no. 2, pp. 135–142, 2015.
[17] P. Zalewski,M. Zawadka-Kunikowska, J. Słomko et al., “Cardio-
vascular and thermal response to dry-sauna exposure in healthy
subjects,” Physiology Journal, vol. 2014, Article ID 106049, 10
pages, 2014.
[18] Z.-D. Zhao, W. Z. Yang, C. Gao et al., “A hypothalamic circuit
that controls body temperature,” Proceedings of the National
Academy of Sciences, 2017.
[19] W. B. Liedtke, “Deconstructing mammalian thermoregulation,”
Proceedings of the National Acadamy of Sciences of the United
States of America, vol. 114, no. 8, pp. 1765–1767, 2017.
[20] M. J. Buono, S. L. Martha, and J. H. Heaney, “Peripheral sweat
gland function, but not whole-body sweat rate, increases in
women following humid heat acclimation,” Journal of Thermal
Biology, vol. 35, no. 3, pp. 134–137, 2010.
[21] M. Zech, S. Bosel, M. Tuthorn et al., “Sauna, sweat and science
– quantifying the proportion of condensation water versus
sweat using a stable water isotope (2H/1H and 18O/16O) tracer
experiment,” Isotopes in Environmental and Health Studies, pp.
1–9, 2015.
[22] M. Iguchi, A. E. Littmann, S.-H. Chang, L. A. Wester, J. S.
Knipper, and R. K. Shields, “Heat stress and cardiovascular,
hormonal, and heat shock proteins in humans,” Journal of
Athletic Training, vol. 47, no. 2, pp. 184–190, 2012.
[23] F. F. Moghadam, M. Bakhshandeh, and H. Sahinbas, “A brief
review of Hyperthermia as a neoadjuvant therapy method
related to cancer treatment,” Journal of Cellular Immunotherapy,
vol. 3, no. 1, p. 8, 2017.
[24] T. Mussivand, H. Alshaer, H. Haddad et al., “Thermal therapy:
a viable adjunct in the treatment of heart failure?” Congestive
Heart Failure, vol. 14, no. 4, pp. 180–186, 2008.
[25] M. A. Petrie, A. L. Kimball, C. L. McHenry et al., “Distinct
skeletal muscle gene regulation from active contraction, passive
vibration, and whole body heat stress in humans,” PLoS ONE,
vol. 11, no. 8, Article ID e0160594, 2016.
[26] J. C. Harvey, B. T. Roseguini, B. M. Goerger, E. A. Fallon,
and B. J. Wong, “Acute thermotherapy prevents impairments in
cutaneous microvascular function induced by a high fat meal,”
Journal of Diabetes Research, vol. 2016, Article ID 1902325, 11
pages, 2016.
[27] A. Garolla, M. Torino, B. Sartini et al., “Seminal and molecular
evidence that sauna exposure affects human spermatogenesis,”
Human Reproduction, vol. 28, no. 4, pp. 877–885, 2013.
[28] K. Kukkonen-Harjula and K. Kauppinen, “Health effects and
risks of sauna bathing,” International Journal of Circumpolar
Health, vol. 65, no. 3, pp. 195–205, 2006.
[29] N. Kluger, “Sauna: cardiac and vascular benefits and risks,” La
Presse Me´dicale, vol. 40, no. 10, pp. 895–899, 2011.
[30] S. Shui, X. Wang, J. Y. Chiang, and L. Zheng, “Far-infrared
therapy for cardiovascular, autoimmune, and other chronic
health problems: a systematic review,” Experimental Biology and
Medicine, vol. 240, no. 10, pp. 1257–1265, 2015.
[31] C. Tei, T. Imamura, K. Kinugawa et al., “Waon therapy for
managing chronic heart failure - Results from a multicenter
prospective randomized WAON-CHF study,” Circulation Jour-
nal, vol. 80, no. 4, pp. 827–834, 2016.
[32] S. Fujita, Y. Ikeda, M. Miyata et al., “Effect of Waon therapy on
oxidative stress in chronic heart failure,”Circulation Journal, vol.
75, no. 2, pp. 348–356, 2011.
[33] S. Kuwahata, M. Miyata, S. Fujita et al., “Improvement of
autonomic nervous activity by Waon therapy in patients with
chronic heart failure,” Journal of Cardiology, vol. 57, no. 1, pp.
100–106, 2011.
[34] T. Shinsato,M.Miyata, T. Kubozono et al., “Waon therapymobi-
lizes CD34+ cells and improves peripheral arterial disease,”
Journal of Cardiology, vol. 56, no. 3, pp. 361–366, 2010.
28 Evidence-Based Complementary and Alternative Medicine
[35] M. Miyata, T. Kihara, T. Kubozono et al., “Beneficial effects of
waon therapy on patients with chronic heart failure: results of
a prospective multicenter study,” Journal of Cardiology, vol. 52,
no. 2, pp. 79–85, 2008.
[36] T. Kihara, S. Biro, Y. Ikeda et al., “Effects of repeated sauna
treatment on ventricular arrhythmias in patients with chronic
heart failure,” Circulation Journal, vol. 68, no. 12, pp. 1146–1151,
2004.
[37] A. Masuda, M. Miyata, T. Kihara, S. Minagoe, and C. Tei,
“Repeated sauna therapy reduces urinary 8-epi-prostaglnadin
F2𝛼,” Japanese Heart Journal, vol. 45, no. 2, pp. 297–303, 2004.
[38] T. Laukkanen, S. Kunutsor, J. Kauhanen, and J. A. Laukkanen,
“Sauna bathing is inversely associated with dementia and
Alzheimer’s disease in middle-aged Finnish men,” Age and
Ageing, 2016.
[39] T. Laukkanen, H. Khan, F. Zaccardi, and J. A. Laukkanen,
“Association between sauna bathing and fatal cardiovascular
and all-cause mortality events,” JAMA Internal Medicine, vol.
175, no. 4, pp. 542–548, 2015.
[40] M. Sobajima, T. Nozawa, H. Ihori et al., “Repeated sauna
therapy improves myocardial perfusion in patients with chron-
ically occluded coronary artery-related ischemia,” International
Journal of Cardiology, vol. 167, no. 1, pp. 237–243, 2013.
[41] Y. Sugahara, M. Ishii, H. Muta, K. Egami, T. Akagi, and T. Mat-
suishi, “Efficacy and safety of thermal vasodilation therapy by
sauna in infants with severe congestive heart failure secondary
to ventricular septal defect,” American Journal of Cardiology,
vol. 92, no. 1, pp. 109–113, 2003.
[42] T. Ohori, T. Nozawa, H. Ihori et al., “Effect of repeated
sauna treatment on exercise tolerance and endothelial function
in patients with chronic heart failure,” American Journal of
Cardiology, vol. 109, no. 1, pp. 100–104, 2012.
[43] R. Beever, “The effects of repeated thermal therapy on quality
of life in patients with type II diabetes mellitus,” The Journal of
Alternative andComplementaryMedicine, vol. 16, no. 6, pp. 677–
681, 2010.
[44] T. Kihara, M. Miyata, T. Fukudome et al., “Waon therapy
improves the prognosis of patients with chronic heart failure,”
Journal of Cardiology, vol. 53, no. 2, pp. 214–218, 2009.
[45] C. Tei, T. Shinsato, M. Miyata, T. Kihara, and S. Hamasaki,
“Waon therapy improves peripheral arterial disease,” Journal of
the American College of Cardiology, vol. 50, no. 22, pp. 2169–
2171, 2007.
[46] H. Miyamoto, H. Kai, H. Nakaura et al., “Safety and efficacy of
repeated sauna bathing in patients with chronic systolic heart
failure: a preliminary report,” Journal of Cardiac Failure, vol. 11,
no. 6, pp. 432–436, 2005.
[47] S. Biro, A. Masuda, T. Kihara, and C. Tei, “Clinical implications
of thermal therapy in lifestyle-related disease,” Experimental
Biology and Medicine, vol. 228, no. 10, pp. 1245–1249, 2003.
[48] T. Kihara, S. Biro,M. Imamura et al., “Repeated sauna treatment
improves vascular endothelial and cardiac function in patients
with chronic heart failure,” Journal of the American College of
Cardiology, vol. 39, no. 5, pp. 754–759, 2002.
[49] M. Imamura, S. Biro, T. Kihara et al., “Repeated thermal therapy
improves impaired vascular endothelial function in patients
with coronary risk factors,” Journal of the American College of
Cardiology, vol. 38, no. 4, pp. 1083–1088, 2001.
[50] G. Kanji, M. Weatherall, R. Peter, G. Purdie, and R. Page,
“Efficacy of regular sauna bathing for chronic tension-type
headache: a randomized controlled study,” The Journal of
Alternative and ComplementaryMedicine, vol. 21, no. 2, pp. 103–
109, 2015.
[51] A. Masuda, Y. Koga, M. Hattanmaru, S. Minagoe, and C.
Tei, “The effects of repeated thermal therapy for patients with
chronic pain,” Psychotherapy and Psychosomatics, vol. 74, no. 5,
pp. 288–294, 2005.
[52] A. Masuda, M. Nakazato, T. Kihara, S. Minagoe, and C. Tei,
“Repeated thermal therapy diminishes appetite loss and sub-
jective complaints in mildly depressed patients,” Psychosomatic
Medicine, vol. 67, no. 4, pp. 643–647, 2005.
[53] F.G. J.Oosterveld, J. J. Rasker,M. Floors et al., “Infrared sauna in
patients with rheumatoid arthritis and ankylosing spondylitis,”
Clinical Rheumatology, vol. 28, no. 1, pp. 29–34, 2009.
[54] K. Amano, R. Yanagihori, and C. Tei, “Waon therapy is effective
as the treatment of myalgic encephalomyelitis/chronic fatigue
syndrome,” Journal of Japanese Association of Physical Medicine
Balneology and Climatology, vol. 78, no. 3, pp. 285–302, 2015.
[55] Y. Soejima, T. Munemoto, A. Masuda, Y. Uwatoko, M. Miyata,
and C. Tei, “Effects of Waon therapy on chronic fatigue
syndrome: a pilot study,” Internal Medicine, vol. 54, no. 3, pp.
333–338, 2015.
[56] S. Matsumoto, M. Shimodozono, S. Etoh, R. Miyata, and
K. Kawahira, “Effects of thermal therapy combining sauna
therapy and underwater exercise in patients with fibromyalgia,”
Complementary Therapies in Clinical Practice, vol. 17, no. 3, pp.
162–166, 2011.
[57] N. Kunbootsri, T. Janyacharoen, P. Arrayawichanon et al., “The
effect of six-weeks of sauna on treatment autonomic nervous
system, peak nasal inspiratory flow and lung functions of
allergic rhinitis Thai patients,” Asian Pacific Journal of Allergy
and Immunology, vol. 31, no. 2, pp. 142–147, 2013.
[58] D. Pach, B. Kno¨chel, R. Lu¨dtke, K. Wruck, S. N. Willich,
and C. M. Witt, “Visiting a sauna: Does inhaling hot dry
air reduce common cold symptoms? A randomised controlled
trial,” Medical Journal of Australia, vol. 193, no. 11-12, pp. 730–
734, 2010.
[59] H. Kikuchi, N. Shiozawa, S. Takata, K. Ashida, and F. Mit-
sunobu, “Effect of repeated waon therapy on exercise tolerance
and pulmonary function in patients with chronic obstructive
pulmonary disease: a pilot controlled clinical trial,” Interna-
tional Journal of Chronic Obstructive Pulmonary Disease, vol. 9,
pp. 9–15, 2014.
[60] M. Umehara, A. Yamaguchi, S. Itakura et al., “Repeated Waon
therapy improves pulmonary hypertension during exercise in
patients with severe chronic obstructive pulmonary disease,”
Journal of Cardiology, vol. 51, no. 2, pp. 106–113, 2008.
[61] J. Stanley, A. Halliday, S. D’Auria, M. Buchheit, and A. S. Leicht,
“Effect of sauna-based heat acclimation on plasma volume and
heart rate variability,” European Journal of Applied Physiology,
vol. 115, no. 4, pp. 785–794, 2015.
[62] V. Zinchuk and D. Zhadzko, “Sauna effect on blood oxy-
gen transport and prooxidant-antioxidant balance in athletes,”
Medicina Sportiva: Journal of Romanian SportsMedicine Society,
vol. 8, no. 3, p. 1883, 2012.
[63] W. Pilch, Z. Szyguła, A. Klimek et al., “Changes in the lipid
profile of blood serumin women taking sauna baths of various
duration,” International Journal of Occupational Medicine and
Environmental Health, vol. 23, no. 2, pp. 167–174, 2010.
[64] D. Kowatzki, C. MacHoldt, K. Krull et al., “Effect of regular
sauna on epidermal barrier function and stratum corneum
water-holding capacity in vivo in humans: a controlled study,”
Dermatology, vol. 217, no. 2, pp. 173–180, 2008.
Evidence-Based Complementary and Alternative Medicine 29
[65] W. Pilch, Z. Szyguta, and M. Torii, “Effect of the sauna-
induced thermal stimuli of various intensity on the thermal and
hormonal metabolism in women,” Biology of Sport, vol. 24, no.
4, pp. 357–373, 2007.
[66] D. Gryka, W. Pilch, M. Szarek, Z. Szygula, and Ł. Tota, “The
effect of sauna bathing on lipid profile in young, physically
active, male subjects,” International Journal of Occupational
Medicine and Environmental Health, vol. 27, no. 4, pp. 608–618,
2014.
[67] W. Pilch, Z. Szyguła, A. Tyka et al., “Effect of 30-minute sauna
sessions on lipid profile in young women,” Medicina Sportiva,
vol. 18, no. 4, pp. 165–171, 2014.
[68] M. Hu¨ppe, J. Mu¨ller, J. Schulze, H. Wernze, and P. Ohnsorge,
“Treatment of patients burdened with lipophilic toxicants: a
randomized controlled trial,” Activitas Nervosa Superior Redi-
viva, vol. 51, no. 3-4, pp. 133–141, 2009.
[69] G. H. Ross and M. C. Sternquist, “Methamphetamine exposure
and chronic illness in police officers: significant improvement
with sauna-based detoxification therapy,” Toxicology & Indus-
trial Health, vol. 28, no. 8, pp. 758–768, 2012.
[70] D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred
reporting items for systematic reviews and meta-analyses: the
PRISMA statement,” PLoS Medicine, vol. 6, no. 7, Article ID
e1000097, 2009.
[71] J. P. T. Higgins, D. G. Altman, P. C. Gøtzsche et al., “The
Cochrane Collaboration’s tool for assessing risk of bias in
randomised trials,” British Medical Journal, vol. 343, no. 7829,
Article ID d5928, 2011.
[72] A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality
of reports of randomized clinical trials: is blinding necessary?”
Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996.
[73] A. Masuda, T. Kihara, T. Fukudome, T. Shinsato, S. Minagoe,
and C. Tei, “The effects of repeated thermal therapy for two
patients with chronic fatigue syndrome,” Journal of Psychoso-
matic Research, vol. 58, no. 4, pp. 383–387, 2005.
[74] C. Tei, “Waon therapy: soothing warmth therapy,” Journal of
Cardiology, vol. 49, no. 6, pp. 301–304, 2007.
[75] O. J. Luurila, “Cardiac arrhythmias, sudden death and the
Finnish sauna bath,” in Sudden Coronary Death, pp. 73–81,
Karger Publishers, Berlin, Germany, 1978.
[76] O. J. Luurila, “The sauna and the heart,” Journal of Internal
Medicine, vol. 231, no. 4, pp. 319-320, 1978.
[77] K. Kukkonen-Harjula, P. Oja, I. Vuori et al., “Cardiovascular
effects of Atenolol, Scopolamine and their combination on
healthy men in Finnish sauna baths,” European Journal of
Applied Physiology, vol. 69, no. 1, pp. 10–15, 1994.
[78] M. L. Keast and K. B. Adamo, “The Finnish sauna bath and
its use in patients with cardiovascular disease,” Journal of
Cardiopulmonary Rehabilitation and Prevention, vol. 20, no. 4,
pp. 225–230, 2000.
[79] J. R. Basford, J. K. Oh, T. G. Allison et al., “Safety, acceptance,
and physiologic effects of sauna bathing in people with chronic
heart failure: a pilot report,” Archives of Physical Medicine and
Rehabilitation, vol. 90, no. 1, pp. 173–177, 2009.
[80] M. Kivima¨ki, M. Virtanen, and J. E. Ferrie, “The link between
sauna bathing and mortality may be noncausal,” JAMA Internal
Medicine, vol. 175, no. 10, p. 1718, 2015.
[81] A. A. Miragem and P. I. H. de Bittencourt, “Nitric oxide-
heat shock protein axis in menopausal hot flushes: neglected
metabolic issues of chronic inflammatory diseases associated
with deranged heat shock response,” Human Reproduction
Update, pp. 1–29, 2017.
[82] A. S. Leon and O. A. Sanchez, “Response of blood lipids to
exercise training alone or combined with dietary intervention,”
Medicine & Science in Sports & Exercise, vol. 33, no. 6, pp. S502–
S515, 2001.
[83] S. J. Genuis, M. E. Sears, G. Schwalfenberg, J. Hope, and
R. Bernhoft, “Clinical detoxification: elimination of persistent
toxicants from the human body,” The Scientific World Journal,
vol. 2013, Article ID 238347, 3 pages, 2013.
[84] M. E. Sears, K. J. Kerr, and R. I. Bray, “Arsenic, cadmium,
lead, and mercury in sweat: a systematic review,” Journal of
Environmental and Public Health, vol. 2012, Article ID 184745,
10 pages, 2012.
[85] S. K. Genuis, D. Birkholz, and S. J. Genuis, “Human excretion of
polybrominated diphenyl ether flame retardants: blood, urine,
and sweat study,” BioMed Research International, vol. 2017,
Article ID 3676089, 14 pages, 2017.
[86] S. J. Genuis, K. Lane, and D. Birkholz, “Human elimination
of organochlorine pesticides: blood, urine, and sweat study,”
BioMed Research International, vol. 2016, Article ID 1624643, 10
pages, 2016.
[87] S. J. Genuis, S. Beesoon, D. Birkholz, and R. A. Lobo, “Human
excretion of bisphenol A: blood, urine, and sweat (BUS) study,”
Journal of Environmental and Public Health, vol. 2012, Article ID
185731, 10 pages, 2012.
[88] S. J. Genuis, S. Beesoon, R. A. Lobo, and D. Birkholz, “Human
elimination of phthalate compounds: blood, urine, and sweat
(BUS) study,”The Scientific World Journal, vol. 2012, Article ID
615068, 10 pages, 2012.
[89] E. J. Cone, M. J. Hillsgrove, A. J. Jenkins, R. M. Keenan, and W.
D. Darwin, “Sweat testing for heroin, cocaine, and metabolites,”
Journal of Analytical Toxicology, vol. 18, no. 6, pp. 298–305, 1994.
[90] N. De Giovanni and N. Fucci, “The current status of sweat test-
ing for drugs of abuse: a review,” Current Medicinal Chemistry,
vol. 20, no. 4, pp. 545–561, 2013.
[91] J. N. Hussain, N. Mantri, and M. M. Cohen, “Working up a
good sweat - The challenges of standardising sweat collection
formetabolomics analysis,”TheClinical Biochemist Reviews, vol.
38, no. 1, pp. 13–34, 2017.
[92] R. Przewlocki, “Opioid Peptides,” in Neuroscience in the 21st
Century, pp. 1525–1553, Springer, Berlin, Germany, 2013.
[93] V. Koljonen, “Hot air sauna burns-review of their etiology and
treatment,” Journal of Burn Care & Research, vol. 30, no. 4, pp.
705–710, 2009.
[94] N. Giannetti, M. Juneau, A. Arsenault et al., “Sauna-induced
myocardial ischemia in patients with coronary artery disease,”
American Journal of Medicine, vol. 107, no. 3, pp. 228–233, 1999.
[95] G. G. R. Sforza andA.Marinou, “Hypersensitivity pneumonitis:
a complex lung disease,” Clinical and Molecular Allergy, vol. 15,
no. 1, article 6, 2017.
[96] K.-J. Chen, T.-H. Chen, Y.-M. Sue, T.-J. Chen, and C.-Y. Cheng,
“High-volume plasma exchange in a patient with acute liver
failure due to non-exertional heat stroke in a sauna,” Journal of
Clinical Apheresis, vol. 29, no. 5, pp. 281–283, 2014.
[97] T. Wessapan and P. Rattanadecho, “Heat transfer analysis of the
human eye during exposure to sauna therapy,” Numerical Heat
Transfer, Part A: Applications, vol. 68, no. 5, pp. 566–582, 2015.
[98] J. G. Heckmann, C. Rauch, S. Seidler, M. Du¨tsch, and B. Kasper,
“Sauna stroke syndrome,” Journal of Stroke and Cerebrovascular
Diseases, vol. 14, no. 3, pp. 138-139, 2005.
[99] A. Kentta¨mies and K. Karkola, “Death in sauna,” Journal of
Forensic Sciences, vol. 53, no. 3, pp. 724–729, 2008.
30 Evidence-Based Complementary and Alternative Medicine
[100] A. Rodhe and A. Eriksson, “Sauna deaths in Sweden, 1992-
2003,”TheAmerican Journal of ForensicMedicine and Pathology,
vol. 29, no. 1, pp. 27–31, 2008.
[101] A. Jung and H.-C. Schuppe, “Influence of genital heat stress on
semen quality in humans,” Andrologia, vol. 39, no. 6, pp. 203–
215, 2007.
[102] H.Guo,H.-G. Zhang, B.-G. Xue, Y.-W. Sha, Y. Liu, andR.-Z. Liu,
“Effects of cigarette, alcohol consumption and sauna on sperm
morphology,” National Journal of Andrology, vol. 12, no. 3, pp.
215–221, 2006.
[103] J. Saikhun, Y. Kitiyanant, V. Vanadurongwan, and K. Pava-
suthipaisit, “Effects of sauna on sperm movement character-
istics of normal men measured by computer-assisted sperm
analysis,” International Journal of Andrology, vol. 21, no. 6, pp.
358–363, 1998.
[104] P. Brown-Woodman, E. Post, G. Gass, and I. White, “The
effect of a single sauna exposure on spermatozoa,” Archives of
Andrology, vol. 12, no. 1, pp. 9–15, 1984.
[105] M. Sarner, “Inconceivable truth,” New Scientist, vol. 236, no.
3152, pp. 28–32, 2017.
[106] S. K. Kunutsor, T. Laukkanen, and J. A. Laukkanen, “Sauna
bathing reduces the risk of respiratory diseases: a long-term
prospective cohort study,” European Journal of Epidemiology,
pp. 1–5, 2017.
[107] S. K. Kunutsor, T. Laukkanen, and J. A. Laukkanen, “Frequent
sauna bathing may reduce the risk of pneumonia in middle-
aged Caucasian men: the KIHD prospective cohort study,”
Respiratory Medicine, vol. 132, pp. 161–163, 2017.
[108] J. A. Laukkanen andT. Laukkanen, “Sauna bathing and systemic
inflammation,” European Journal of Epidemiology, pp. 1–3, 2017.
[109] F. Zaccardi, T. Laukkanen, P. Willeit, S. K. Kunutsor, J.
Kauhanen, and J. A. Laukkanen, “Sauna bathing and incident
hypertension: a prospective cohort study,” American Journal of
Hypertension, 2017.
[110] S. K. Kunutsor, H. Khan, T. Laukkanen, and J. A. Laukkanen,
“Joint associations of sauna bathing and cardiorespiratory
fitness on cardiovascular and all-cause mortality risk: a long-
termprospective cohort study,”Annals ofMedicine, pp. 1–8, 2017.
